[{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"Biomind Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Mebufotenin","moa":"5-HT2A receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Biomind Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Sublingual Tablet","sponsorNew":"Biomind Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biomind Labs \/ Inapplicable"},{"orgOrder":0,"company":"Raya Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Fasudil","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Raya Therapeutic","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Raya Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Raya Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Akanda Corp","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Akanda Corp","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Akanda Corp"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Alpha Blue Ocean","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Financing","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Alpha Blue Ocean","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Alpha Blue Ocean"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Private Placement","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Nasal Inhalation Powder in Capsule","sponsorNew":"Tetra BioPharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Bloom Burton Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Public Offering","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Bloom Burton Securities","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Bloom Burton Securities"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Nuance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Nuance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Nuance Pharma"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"PharmaTher","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2021","type":"Inapplicable","leadProduct":"Ketamine Hydrochloride","moa":"NMDA receptor","graph1":"Neurology","graph2":"Phase II","graph3":"PharmaTher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"PharmaTher \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"PharmaTher \/ Inapplicable"},{"orgOrder":0,"company":"Firefly Neuroscience","sponsor":"Bright Minds Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Collaboration","leadProduct":"BMB-101","moa":"5-HT2C receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Firefly Neuroscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Firefly Neuroscience \/ Bright Minds Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Firefly Neuroscience \/ Bright Minds Biosciences"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WEX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"WEX Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Tetrodotoxin","moa":"NaV Channel","graph1":"Neurology","graph2":"Phase II","graph3":"WEX Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"WEX Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"WEX Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tetra BioPharma","sponsor":"Cannvalate","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Tetrahydrocannabinol","moa":"||CB1\/CB2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Tetra BioPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Aerosol","sponsorNew":"Tetra BioPharma \/ Cannvalate","highestDevelopmentStatusID":"8","companyTruncated":"Tetra BioPharma \/ Cannvalate"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Antibe Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Otenaproxesul","moa":"COX-2","graph1":"Neurology","graph2":"Phase II","graph3":"Antibe Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Antibe Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Antibe Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"MediPharm Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Neurology","graph2":"Phase II","graph3":"MediPharm Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MediPharm Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"MediPharm Labs \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska University Hospital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska University Hospital","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska University Hospital"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Inapplicable"},{"orgOrder":0,"company":"IntelGenx","sponsor":"Karolinska Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Montelukast Sodium","moa":"CysLT1","graph1":"Neurology","graph2":"Phase II","graph3":"IntelGenx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Buccal Film","sponsorNew":"IntelGenx \/ Karolinska Institute","highestDevelopmentStatusID":"8","companyTruncated":"IntelGenx \/ Karolinska Institute"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"NBI-921352","moa":"Nav1.6 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences"},{"orgOrder":0,"company":"Xenon Pharmaceuticals Inc","sponsor":"Neurocrine Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"NBI-921352","moa":"Nav1.6 channel","graph1":"Neurology","graph2":"Phase II","graph3":"Xenon Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences","highestDevelopmentStatusID":"8","companyTruncated":"Xenon Pharmaceuticals Inc \/ Neurocrine Biosciences"}]

Find Neurology Drugs in Phase II Clinical Development in CANADA

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The collaboration aims to analyze the data from its first-in-human Phase 1 of BMB-101, a highly selective 5-HT2C, Gq-protein biased agonist, for neuropsychiatric disorders and epilepsy.

                          Product Name : BMB-101

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          October 16, 2024

                          Lead Product(s) : BMB-101

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Bright Minds Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Montelukast VersaFilm (montelukast) is a leukotriene receptor antagonist, which is being evaluated in patients with Parkinson’s Disease, the second most common neurodegenerative disease.

                          Product Name : Montelukast VersaFilm

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 04, 2024

                          Lead Product(s) : Montelukast Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : RT1968 (fasudil) is a small molecule inhibitor of the rho-associated kinase (ROCK), being evaluated for the treatment of amyotrophic lateral sclerosis.

                          Product Name : RT1968

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 17, 2024

                          Lead Product(s) : Fasudil

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Montelukast VersaFilm (montelukast) is a small molecule CysLT1 receptor inhibitor, given in the form of buccal film, is currently being ivestigated for patients with alzheimer's disease.

                          Product Name : Montelukast VersaFilm

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 07, 2024

                          Lead Product(s) : Montelukast Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : BMND08 (5-MeO-DMT) is a 5-HT1A receptor agonist, small molecule drug candidate. It is being evaluated for the treatment of depression & anxiety in alzheimer’s disease.

                          Product Name : BMND08

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          February 29, 2024

                          Lead Product(s) : Mebufotenin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.

                          Product Name : Montelukast VersaFilm

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 14, 2023

                          Lead Product(s) : Montelukast Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Halneuron (tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels, being developed for Neuropathic Pain.

                          Product Name : Halneuron

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 12, 2023

                          Lead Product(s) : Tetrodotoxin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.

                          Product Name : Montelukast VersaFilm

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 02, 2023

                          Lead Product(s) : Montelukast Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Karolinska Institute

                          Deal Size : $2.0 million

                          Deal Type : Collaboration

                          blank

                          09

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Halneuron (Tetrodotoxin injectable formulation), a selective sodium channel blocker, produces analgesia either by decreasing the propagation of action potentials by sodium channels and/or by blocking ectopic discharges associated with chronic pain.

                          Product Name : Halneuron

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 01, 2023

                          Lead Product(s) : Tetrodotoxin

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.

                          Product Name : Montelukast VersaFilm

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 08, 2023

                          Lead Product(s) : Montelukast Sodium

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank